ClinicalTrials.gg
Not yet recruitingNCT07868393PROTECT-EDUpdated Oct 9, 2026

Prevention and Rapid Outreach for Treatment, Engagement, and Care Transition From the Emergency Department

An interventional study of PROTECT-ED Care Coordination in Opioid Overdose Prevention, HIV Prevention and Care and Harm Reduction, sponsored by Johns Hopkins University. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by Johns Hopkins University · Not applicable, Interventional, and Health services research

Updated Oct 9, 2026Newly registeredGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The Prevention and Rapid Outreach for Treatment, Engagement, and Care Transition from the Emergency Department (PROTECT-ED) study evaluates an emergency department-based implementation strategy designed to improve delivery of evidence-based overdose and HIV prevention services during community re-entry.

Read the detailed description
  1. Background Individuals returning to the community following incarceration experience one of the highest periods of preventable morbidity and mortality observed in clinical medicine. During the weeks and months following release from correctional facilities, rates of fatal opioid overdose increase by as much as 10- to 100-fold, while the risk of HIV acquisition is estimated to be 6- to 20-fold higher than that of the general population. These risks reflect the convergence of opioid use disorder, disrupted healthcare access, unstable housing, poverty, stigma, untreated mental illness, and fragmented transitions between correctional and community healthcare systems. Although effective biomedical interventions exist--including medications for opioid use disorder (MOUD) and HIV pre-exposure prophylaxis (PrEP)--many recently incarcerated individuals do not successfully engage in or remain connected to these services during community re-entry.

    Historically, efforts to improve continuity of care have focused on correctional health systems and community re-entry programs. These approaches have demonstrated important benefits but remain limited by incomplete implementation, inconsistent access across jurisdictions, and substantial loss to follow-up during the transition from incarceration to community living. Consequently, many individuals with ongoing opioid-related and HIV-related risks remain disconnected from preventive healthcare during the period of greatest vulnerability.

    The emergency department represents an underutilized opportunity to address this implementation gap. Between one-quarter and one-half of individuals released from incarceration seek care in an emergency department within the first year following release, and for many, the emergency department serves as the only point of contact with the healthcare system. Contemporary emergency departments have increasingly expanded beyond episodic acute care to incorporate evidence-based public health interventions, including overdose prevention, medications for opioid use disorder, HIV screening, and initiation of HIV pre-exposure prophylaxis. These developments position the emergency department as a critical venue for delivering integrated preventive services to individuals who may otherwise remain unreached by traditional healthcare systems.

    PROTECT-ED was developed to leverage this unique healthcare touchpoint by integrating peer-delivered prevention services, evidence-based biomedical prevention, harm reduction, and facilitated linkage to ongoing community care into a single emergency department encounter. Rather than evaluating the efficacy of MOUD or PrEP--which are already supported by extensive evidence--the study evaluates an implementation strategy designed to improve the reach, uptake, and continuity of these established interventions among recently incarcerated individuals. The intervention is informed by the Behavioral Model for Vulnerable Populations, which recognizes that healthcare utilization is shaped by predisposing characteristics, enabling resources, and perceived and evaluated need for care. By addressing barriers across each of these domains during an existing emergency department visit, PROTECT-ED seeks to improve engagement with preventive services during community re-entry.

  2. Study Objectives As a clinical trial planning study, the purpose of PROTECT-ED is to refine the intervention through participatory prototyping, evaluate the feasibility and preliminary clinical outcomes of implementation, and characterize implementation processes that will inform a future multicenter effectiveness-implementation trial. The knowledge generated through this study will provide the empirical and operational foundation necessary to scale emergency department-based overdose and HIV prevention strategies for individuals returning from incarceration nationally. The overarching objective of PROTECT-ED is to refine and evaluate an emergency department-based implementation strategy designed to improve uptake of evidence-based overdose and HIV prevention services among adults recently released from incarceration. Specifically, this study seeks to refine the intervention through stakeholder engagement, evaluate the feasibility and preliminary clinical outcomes of implementation, and characterize implementation processes to inform a future multi-center effectiveness-implementation trial.
  3. Aims The study consists of three integrated aims. Aim 1 focuses on refinement of the PROTECT-ED intervention through participatory prototyping involving individuals with lived experience, clinicians, correctional health partners, community-based organizations, and other stakeholders.

    Aim 2 evaluates the feasibility and preliminary clinical outcomes of the refined PROTECT-ED intervention through a prospective implementation trial enrolling 120 adults recently released from incarceration.

    Aim 3 evaluates implementation outcomes using mixed methods guided by the Practical, Robust, Implementation and Sustainability Model (PRISM). Quantitative and qualitative findings will characterize intervention reach, acceptability, contextual determinants, and implementation barriers and facilitators.

  4. Study Setting The study will be conducted within the Johns Hopkins Hospital Emergency Department, an urban, academic emergency department that evaluates approximately 60,000 adult patients annually. The emergency department has established clinical pathways for the identification and management of opioid use disorder, universal opt-out HIV screening, initiation of HIV pre-exposure prophylaxis, peer recovery services, and linkage to addiction medicine and infectious diseases care. The Johns Hopkins Hospital Emergency Department serves a large population of individuals affected by opioid use disorder, homelessness, structural vulnerability, and criminal-legal involvement.
  5. Conceptual Framework The PROTECT-ED intervention is informed by the Behavioral Model for Vulnerable Populations, which recognizes that healthcare utilization is influenced by predisposing characteristics, enabling resources, and perceived and evaluated need for care. The intervention seeks to improve engagement with overdose and HIV prevention services by addressing barriers across each of these domains during an emergency department encounter.

    Evaluation of implementation outcomes is guided by the Practical, Robust, Implementation and Sustainability Model (PRISM). PRISM provides a framework for understanding the interaction between the intervention, recipients, organizational context, external environment, and implementation infrastructure, and will inform refinement of the intervention and planning for future scale-up.

  6. Study Timeline The anticipated duration of the study is 36 months. Year 1: Regulatory approvals, participatory prototyping (Aim 1), intervention refinement, and study start-up.

Years 2-3: Participant enrollment, intervention delivery, follow-up assessments, and implementation evaluation (Aims 2 and 3).

Year 3: Data analysis, dissemination of findings, and development of a future multicenter effectiveness-implementation trial.

02

Conditions studied

  • Opioid Overdose Prevention
  • HIV Prevention and Care
  • Harm Reduction

Browse trials for

Keywords

  • Harm reduction
  • OUD
  • Justice-Involved Individuals
  • Healthcare Engagement
03

In context

Harm Reduction

56 studies on the registry are indexed under Harm Reduction; 32 are open to participants now.

This study's planned enrollment of 120 is below the median of 161 across 45 interventional studies indexed under Harm Reduction.

Browse Harm Reduction studies →

Lead sponsor

Johns Hopkins University is the lead sponsor of 1,809 studies on the registry; 314 are open to participants now.

Of its 208 completed or terminated interventional studies of FDA-regulated products, 144 (69%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Are 18 years of age or older.
  • Present to the Johns Hopkins Hospital Emergency Department.
  • Have been released within the previous 180 days from a prison, jail, juvenile detention facility, immigration detention facility, halfway house, residential reentry center, or other correctional setting. Recent incarceration may be confirmed through participant self-report, electronic medical record documentation, the Victim Information and Notification Everyday (VINE) system, or other available documentation. Participant self-report alone is sufficient to establish eligibility.
  • Meet criteria for opioid use disorder or hazardous opioid use and are considered appropriate for evaluation for medications for opioid use disorder (MOUD) or are at risk for HIV acquisition.
  • Able to speak and understand communicate in English sufficiently to provide informed consent and complete study assessments.
  • Provide informed consent.
  • Have a reliable telephone number for study follow-up.

Exclusion criteria

Exclusion Criteria:

  • Inability to provide informed consent during the index emergency department encounter.
  • Lack of a reliable telephone number for study follow-up.
  • Prior enrollment in the PROTECT-ED study.
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Other
    Aim 2 Study Participants

    Participants will receive the PROTECT-ED intervention during the index emergency department encounter. The intervention consists of systematic identification; peer-delivered prevention services; same-day offer and initiation of MOUD and PrEP, when clinically appropriate; harm reduction services; and facilitated linkage to ongoing community care. Clinical decisions regarding medication initiation remain the responsibility of the treating emergency department clinician. The ED clinician would prescribe medication as part of ED care delivery, this would include reviewing eligibility and dosing with the ED pharmacist.

    Behavioral: PROTECT-ED Care Coordination

Interventions

  • BehavioralPROTECT-ED Care Coordination

    Participants will receive the PROTECT-ED intervention during the index emergency department encounter. The intervention consists of systematic identification; peer-delivered prevention services; same-day offer and initiation of MOUD and PrEP, when clinically appropriate; harm reduction services; and facilitated linkage to ongoing community care. Clinical decisions regarding medication initiation remain the responsibility of the treating emergency department clinician. The ED clinician would prescribe medication as part of ED care delivery, this would include reviewing eligibility and dosing with the ED pharmacist.

06

What researchers measure

Primary outcomes

  1. MOUD uptake

    Proportion of participants initiating MOUD

    Time frame: 0-26 Weeks

  2. MOUD and PrEP Uptake

    Proportion of participants initiating MOUD and PrEP

    Time frame: 0-26 Weeks

  3. PrEP Uptake

    Proportion of participants initiating PrEP

    Time frame: 0-26 Weeks

Secondary outcomes

  1. MOUD persistence at 6 months

    Proportion of participants on MOUD at 6 months among those who initiated

    Time frame: 26 Weeks

  2. PrEP persistence at 6 months

    Proportion of participants on PrEP at 6 months among those who initiated

    Time frame: 26 Weeks

  3. Participants with Repeat emergency department utilization

    Repeat emergency department utilization across Baltimore City

    Time frame: 0-26 Weeks

  4. Opioid overdose events

    Proportion of participants with 1+ opioid overdose events

    Time frame: 0-26 Weeks

  5. Linkage and engagement in longitudinal care

    Proportion of participants linked to care

    Time frame: 0-26 Weeks

07

Study locations

1 site
  • The Johns Hopkins Hospital Emergency Department
    Baltimore, Maryland 21287, United States
08

References and documents

Publications

  • Vargas C, Zorbas C, Longworth GR, Ugalde A, Needham C, Sunil A, Venegas Hargous C, Bennett R, Forrester-Bowling T, Cardoso Richter AP, Allender S. Exploring co-design: a systematic review of concepts, processes, models, and frameworks used in public health research. J Public Health (Oxf). 2025 Dec 1;47(4):e616-e639. doi: 10.1093/pubmed/fdaf084. PubMed 40796276 ↗
  • Rousham E, Pareja RG, Creed-Kanashiro HM, Bartolini R, Pradeilles R, Ortega-Roman D, Holdsworth M, Griffiths P, Verdezoto N. Designing intervention prototypes to improve infant and young child nutrition in Peru: a participatory design study protocol. BMJ Open. 2023 Dec 9;13(12):e071280. doi: 10.1136/bmjopen-2022-071280. PubMed 38070935 ↗
  • Goldfarb DA. Surgical adrenal disorders. Semin Nephrol. 1994 Nov;14(6):570-9. No abstract available. PubMed 7855463 ↗
  • Gelberg L, Andersen RM, Leake BD. The Behavioral Model for Vulnerable Populations: application to medical care use and outcomes for homeless people. Health Serv Res. 2000 Feb;34(6):1273-302. PubMed 10654830 ↗
  • Eswaran V, Raven MC, Wang RC, Cawley C, Izenberg JM, Kanzaria HK. Understanding the association between frequent emergency department use and jail incarceration: A cross-sectional analysis. Acad Emerg Med. 2022 May;29(5):606-614. doi: 10.1111/acem.14437. Epub 2022 Feb 10. PubMed 35064709 ↗
  • Easter MM, Schramm-Sapyta NL, Tackett MA, Larsen IG, Tang B, Ralph MA, Huynh LN. Reliance on Community Emergency Departments by People Ever Detained in Jail: Retrospective Cross-Sectional Study. J Correct Health Care. 2023 Aug;29(4):282-292. doi: 10.1089/jchc.22.02.0011. Epub 2023 Jun 19. PubMed 37335965 ↗
  • Bazin H. Is antiinfectious defence thymus-dependent? Ann Inst Pasteur Immunol. 1988 Mar-Apr;139(2):187-9. doi: 10.1016/0769-2625(88)90040-2. No abstract available. PubMed 3259426 ↗
  • Humphreys J, Ahalt C, Stijacic-Cenzer I, Widera E, Williams B. Six-Month Emergency Department Use among Older Adults Following Jail Incarceration. J Urban Health. 2018 Aug;95(4):523-533. doi: 10.1007/s11524-017-0208-4. PubMed 29204845 ↗
  • Meyer JP, Qiu J, Chen NE, Larkin GL, Altice FL. Frequent emergency department use among released prisoners with human immunodeficiency virus: characterization including a novel multimorbidity index. Acad Emerg Med. 2013 Jan;20(1):79-88. doi: 10.1111/acem.12054. PubMed 23570481 ↗
  • Westergaard RP, Spaulding AC, Flanigan TP. HIV among persons incarcerated in the USA: a review of evolving concepts in testing, treatment, and linkage to community care. Curr Opin Infect Dis. 2013 Feb;26(1):10-6. doi: 10.1097/QCO.0b013e32835c1dd0. PubMed 23221766 ↗
  • Iroh PA, Mayo H, Nijhawan AE. The HIV Care Cascade Before, During, and After Incarceration: A Systematic Review and Data Synthesis. Am J Public Health. 2015 Jul;105(7):e5-16. doi: 10.2105/AJPH.2015.302635. Epub 2015 May 14. PubMed 25973818 ↗
  • Spittal MJ, Forsyth S, Pirkis J, Alati R, Kinner SA. Suicide in adults released from prison in Queensland, Australia: a cohort study. J Epidemiol Community Health. 2014 Oct;68(10):993-8. doi: 10.1136/jech-2014-204295. Epub 2014 Jul 9. PubMed 25009152 ↗
  • Wang EA, Wang Y, Krumholz HM. A high risk of hospitalization following release from correctional facilities in Medicare beneficiaries: a retrospective matched cohort study, 2002 to 2010. JAMA Intern Med. 2013 Sep 23;173(17):1621-8. doi: 10.1001/jamainternmed.2013.9008. PubMed 23877707 ↗
  • Hartung DM, McCracken CM, Nguyen T, Kempany K, Waddell EN. Fatal and nonfatal opioid overdose risk following release from prison: A retrospective cohort study using linked administrative data. J Subst Use Addict Treat. 2023 Apr;147:208971. doi: 10.1016/j.josat.2023.208971. Epub 2023 Feb 10. PubMed 36821990 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Oct 2027, 11 months later.

Of 34 interventional studies with no phase under Harm Reduction, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 50. This study's planned 11 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 5, 2026
First posted
Oct 9, 2026
StartEst.
Nov 1, 2026
Primary completionEst.
Oct 1, 2027
CompletionEst.
Oct 1, 2028
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07868393
Responsible party
Sponsor
First posted
Oct 9, 2026
Start date
Nov 1, 2026 (estimated)
Primary completion
Oct 1, 2027 (estimated)
Completion
Oct 1, 2028 (estimated)
Last update
Oct 9, 2026

Study contacts

Bhakti Hansoti, MBChB, PhD, MPH
Contact
bhansot1@jh.edu
410-955-5000
Chris Hoffmann, MD, MSc, MPH
Contact
choffmann@jhmi.edu
Bhakti Hansoti, MBChB, PhD, MPH
principal investigator · Johns Hopkins University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion